12,372 trials
Candidiasis, Invasive · Candidemia
Primary: Percentage of Participants With Global Success at End of Treatment as Determined by the Data Monitoring Committee — 21 Participants
Myelodysplastic Syndromes · Chronic Myelomonocytic Leukemia · Acute Myeloid Leukemia
Primary: Total 5-day Area Under the Curve From 0 to 24 Hours (AUC0-24) After Treatment With ASTX727 And IV Decitabine — 864.34; 855.96; 910.1; 900.5 hours*nanograms per…
Hypogonadism, Male
Primary: Change From Baseline in 24-hour Average Ambulatory Systolic Blood Pressure After 120 Days Treatment — 128.9; 130.6; 1.7 mmHg
Mycobacterium Infections, Nontuberculous
Primary: Psychometric Cross-Sectional Validation of Patient Reported Outcome (PRO): Patient Global Impression of Severity (PGI-S) Respiratory Scale Score at Baseline — 2.5; 2.4…
Malignant Neoplasm of Breast
Primary: Pathologic Complete Response — 18; 15 Participants — p=0.73
Prostate Cancer · Prostatic Neoplasm · Prostatic Neoplasms, Castration-Resistant
Primary: Sensitivity of Ga 68-labeled PSMA-11 Positron Emission Tomography/Computed Tomography (PET/CT) for the Detection on a Per Patient Basis — 1.0 proportion of participants
Extensive Stage Small Cell Lung Carcinoma · Limited Stage Small Cell Lung Carcinoma
Primary: Number of Participants With Deterioration in HVLT-R Delayed Recall Score at Six Months (Phase III) — 33; 27 Participants — p=0.28
Amyloidosis · Amyloid Cardiomyopathy · Transthyretin Amyloidosis
Primary: A Hierarchical Combination of All-Cause Mortality, Cumulative Frequency of CV-related Hospitalization, Change From Baseline in NT-proBNP and Change From Baseline in 6MWT…
Pediatric Central Nervous System Tumor
Primary: Sensitivity and Specificity of Tozuleristide Fluorescence to Detect Tumor in Equivocal (Ambiguous) Tissue During Surgery When Imaged With the Canvas System — 79.8; 34.7…
Bladder Cancer · Bladder Tumor · Muscle-Invasive Bladder Cancer
Primary: Pathologic Complete Response (pCR) Rate- Nivolumab + Bempegaldesleukin Compared to Standard of Care — 10.8; 2.5 Percentage of participants
COVID-19 · Viral Respiratory Illnesses
Primary: The Proportion of Subjects With Symptomatic Laboratory-confirmed COVID-19 Identified After Start of Treatment and Before the End of the 6-week Treatment Period. — 0.02…
Type2 Diabetes
Primary: Change in Percentage of HbA1c From Baseline to 3 Months — 1.6 change in percentage of HbA1c
Cachexia; Cancer · Non Small Cell Lung Cancer
Primary: Mean Change From Baseline in Body Weight Over 12 Weeks — 1.938; 0.594 Change from baseline in body weight (kg) — p=<0.0001
Dry Eye Disease (DED)
Primary: Change From Baseline in Total Staining Score at Day 90 in the Study Eye — -4.5; -3.4 score on a scale — p=0.0475
Cachexia; Cancer · Non Small Cell Lung Cancer
Primary: Mean Change From Baseline in Body Weight Over 12 Weeks — 1.822; 0.538 kg — p=<0.0001